Human Microbiome Market

Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings.

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of microbiome therapeutics and their developers, providing information on preclinical and clinical drugs.  A detailed assessment of the current market landscape of microbiome diagnostic and screening / profiling tests and their providers.  A detailed overview of various industry and non-industry providers of fecal microbiota therapies, along with information on ongoing clinical trials evaluating FMTs for various indications.  An analysis of the start-ups / small firms enagegd in the development of microbiome therapeutics based on various relevant parameters.  An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them.  An analysis of partnerships that have been established since 2017 by the companies engaged in this domain.  An detailed analysis of the investments made in the development of microbiopme therapeutics, diagnostics and screening / profiling tests and FMTs.  An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with an indicative list of contract manufacturers.  A detailed market forecast for microbiome therapeutics and diagnostic tests, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Product  Probiotic Drugs  Other Drugs  Target Indication  Colorectal Cancer  Diabetes Mellitus  Inflammatory Bowel Disease  Irritable Bowel Syndrome  Graft versus Host Disease  Necrotizing Enterocolitis  Primary Hyperoxaluria  Recurrent CDI  Therapeutic Areas  Digestive and Gastrointestinal Disorders  Infectious Diseases  Metabolic Disorders  Rare Disorders  Oncological Disorders  Route of Administration  Oral  Rectal

 Type of Formulation  Capsules  Suspensions  Enemas  Key Geographical Regions  North America  Europe  Asia Pacific

The report also includes detailed profiles of the companies (listed below) engaged in developing microbiome therapeutics, diagnostics and screening / profiling test; each profile features an overview of the company, its financial information (if available), details on its product portfolio, recent developments, and an informed future outlook.  4D Pharma  Biosotia Microbiomics  DNA Genotek  Finch Therapeutics  GoodGut  Infant Bacterial Therapeutics  Invivo Healthcare  MaaT Pharma  OxThera  Qu Biologics  Rebiotix  Seres Therapeutics  Servatus  Shoreline Biome

To view more details on this report, click on the link https://www.rootsanalysis.com/reports/human-microbiome-market/281.html

Learn from experts: do you know about these emerging industry trends? Top 5 Companies Developing Allogeneic Cell Therapies Top 9 Antibody Discovery Companies offering Antibody Discovery Platforms

About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com